Literature DB >> 19167484

Enhanced clonogenic survival induced by protein tyrosine phosphatase (PTP) inhibition after Cr(VI) exposure is mediated by c-Raf and Ras activity.

Dongsoon Bae1, Tura C Camilli, Ngoc-Tram Ha, Susan Ceryak.   

Abstract

Our recent studies showed that maintenance of protein tyrosine phosphorylation by PTP inhibition enhanced cell growth, clonogenic survival, and mutagenesis after a single low-level Cr(VI) exposure, thereby suggesting that tyrosine phosphorylation-dependent signaling may govern inappropriate survival in human lung fibroblasts (HLFs). Our goal is to identify specific phospho-tyrosine regulator(s)/ downstream effectors involved in enhanced survival after Cr(VI) exposure and PTP inhibition. Phosphotyrosine profiling array showed that PTP inhibition following Cr(VI) exposure increased tyrosine phosphorylation of specific proteins, such as FGR and ABL, which are upstream regulators of both Erk and Akt pathways. To explore the roles of these pathways in the PTP-induced increase in clonogenic survival after Cr(VI) exposure, we examined the effect of combined Akt1 and Erk1/2 knockdown via siRNA technology. Akt1 and/or Erk1/2 silencing had no effect on the PTP inhibitor-induced increase in survival following Cr(VI) exposure, suggesting the presence of non-Akt/non-Erk-mediated survival signaling. Interestingly, geldanamycin, an HSP90 inhibitor and non-specific Raf inhibitor, abrogated the PTP inhibitor-mediated increase in survival following Cr(VI) exposure and abolished the expression/activity of c-Raf and activity of Mek. These findings prompted us to explore upstream regulators of Erk, i.e., Ras, c-Raf and Mek for their potential roles in clonogenic survival. GW5074, a specific c-Raf kinase inhibitor did not alter the effect of the PTP inhibitor but decreased Cr(VI)-mediated clonogenic lethality, potentially though Mek hyperactivation. A genetic approach with a c/a Mek1 mutant also showed that Mek activity was not directly associated with the PTP inhibitor effect. Finally, a genetic approach with d/n or c/a Ras and c-Raf mutants, showed that Ras and c-Raf activities play a substantive role in enhancing clonogenic survival by PTP inhibition following Cr(VI) insult. In conclusion, these studies highlight a novel pro-survival mechanism for clonogenic survival in the face of genotoxic stress in the presence of PTP inhibition via an Erk/Mek-independent and Ras/c-Raf-dependent regulation in normal human lung fibroblasts.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19167484      PMCID: PMC2673100          DOI: 10.1016/j.cellsig.2009.01.011

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.850


  48 in total

1.  Nuclear localization of mitogen-activated protein kinase kinase 1 (MKK1) is promoted by serum stimulation and G2-M progression. Requirement for phosphorylation at the activation lip and signaling downstream of MKK.

Authors:  N S Tolwinski; P S Shapiro; S Goueli; N G Ahn
Journal:  J Biol Chem       Date:  1999-03-05       Impact factor: 5.157

2.  A synthetic inhibitor of the mitogen-activated protein kinase cascade.

Authors:  D T Dudley; L Pang; S J Decker; A J Bridges; A R Saltiel
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

Review 3.  Signal transduction through MAP kinase cascades.

Authors:  T S Lewis; P S Shapiro; N G Ahn
Journal:  Adv Cancer Res       Date:  1998       Impact factor: 6.242

Review 4.  Role of the adapter protein CRKL in signal transduction of normal hematopoietic and BCR/ABL-transformed cells.

Authors:  M Sattler; R Salgia
Journal:  Leukemia       Date:  1998-05       Impact factor: 11.528

5.  Transformation of mammalian cells by constitutively active MAP kinase kinase.

Authors:  S J Mansour; W T Matten; A S Hermann; J M Candia; S Rong; K Fukasawa; G F Vande Woude; N G Ahn
Journal:  Science       Date:  1994-08-12       Impact factor: 47.728

6.  Sodium orthovanadate enhances proliferation of progenitor cells in the adult rat subventricular zone after focal cerebral ischemia.

Authors:  Jun Matsumoto; Motohiro Morioka; Yu Hasegawa; Takayuki Kawano; Yutaka Yoshinaga; Tatsumi Maeda; Shigetoshi Yano; Yutaka Kai; Kohji Fukunaga; Jun-ichi Kuratsu
Journal:  J Pharmacol Exp Ther       Date:  2006-06-16       Impact factor: 4.030

7.  Hsp90 functions to balance the phosphorylation state of Akt during C2C12 myoblast differentiation.

Authors:  Bo-Geon Yun; Robert L Matts
Journal:  Cell Signal       Date:  2005-12       Impact factor: 4.315

8.  Src-family tyrosine kinase fyn phosphorylates phosphatidylinositol 3-kinase enhancer-activating Akt, preventing its apoptotic cleavage and promoting cell survival.

Authors:  X Tang; Y Feng; K Ye
Journal:  Cell Death Differ       Date:  2006-07-14       Impact factor: 15.828

Review 9.  Novel targets for lung cancer therapy: part II.

Authors:  Grace K Dy; Alex A Adjei
Journal:  J Clin Oncol       Date:  2002-07-01       Impact factor: 44.544

10.  Bypass of hexavalent chromium-induced growth arrest by a protein tyrosine phosphatase inhibitor: enhanced survival and mutagenesis.

Authors:  Dongsoon Bae; Tura C Camilli; Gina Chun; Madhu Lal; Kristen Wright; Travis J O'Brien; Steven R Patierno; Susan Ceryak
Journal:  Mutat Res       Date:  2008-10-21       Impact factor: 2.433

View more
  3 in total

Review 1.  Chromium genotoxicity: A double-edged sword.

Authors:  Kristen P Nickens; Steven R Patierno; Susan Ceryak
Journal:  Chem Biol Interact       Date:  2010-04-27       Impact factor: 5.192

2.  Raf-independent, PP2A-dependent MEK activation in response to ERK silencing.

Authors:  Dongsoon Bae; Susan Ceryak
Journal:  Biochem Biophys Res Commun       Date:  2009-05-22       Impact factor: 3.575

3.  C-Raf is associated with disease progression and cell proliferation in a subset of melanomas.

Authors:  Lucia B Jilaveanu; Christopher R Zito; Saadia A Aziz; Patricia J Conrad; John C Schmitz; Mario Sznol; Robert L Camp; David L Rimm; Harriet M Kluger
Journal:  Clin Cancer Res       Date:  2009-09-08       Impact factor: 13.801

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.